Publications
Detailed Information
Hydroxyapatite-binding albumin nanoclusters for enhancing bone tumor chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Nae-Won | - |
dc.contributor.author | Lee, Jae-Young | - |
dc.contributor.author | Kim, Dae-Duk | - |
dc.date.accessioned | 2024-04-26T00:24:00Z | - |
dc.date.available | 2024-04-26T00:24:00Z | - |
dc.date.created | 2022-02-04 | - |
dc.date.issued | 2022-02 | - |
dc.identifier.citation | Journal of Controlled Release, Vol.342, pp.111-121 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://hdl.handle.net/10371/199463 | - |
dc.description.abstract | Hydroxyapatite-binding albumin nanoclusters (NCs) were developed for improving the anticancer agent accumulation in bone tumors. Human serum albumin (HSA) was decorated with alendronate (AD), and doxorubicin (DOX)-loaded NCs (HSA-AD/DOX) were fabricated via the ball-milling technology, an innovative nanofabrication method by which more than 90% of the secondary structures of albumin can be preserved. The targeting ability of NCs was confirmed using a novel in vitro bone cancer model, wherein hydroxyapatite and collagen, the major components of the bone matrix representing the highly mineralized bone tumor microenvironment, were co-cultured with HOS/MNNG, a human osteosarcoma cell line. The binding affinity of HSA-AD/ DOX to hydroxyapatite was evaluated based on the DOX binding efficiency. HSA-AD/DOX showed a 5.04-fold higher affinity than HSA/DOX. The enhanced distribution of HSA-AD/DOX to bone tumors was verified using a newly developed mouse model bearing HOS/MNNG tumors with hydroxyapatite beads. HSA-AD/DOX led to a 52.0% increase in tumor accumulation compared to that of the unmodified HSA/DOX. This is mainly due to the hydroxyapatite-binding affinity of the AD moiety, which is supported by histological analyses performed on the dissected tumors. Furthermore, HSA-AD/DOX changed the protein expression patterns of the tumors, implying the enhanced apoptotic process. Overall, the targeting ability of HSA-AD/DOX are effectively translated into improved therapeutic efficacy in bone tumor-xenografted mice, suggesting that the developed NCs are a promising delivery system for bone tumor treatment. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | Hydroxyapatite-binding albumin nanoclusters for enhancing bone tumor chemotherapy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jconrel.2021.12.039 | - |
dc.citation.journaltitle | Journal of Controlled Release | - |
dc.identifier.wosid | 000746795800004 | - |
dc.identifier.scopusid | 2-s2.0-85122286728 | - |
dc.citation.endpage | 121 | - |
dc.citation.startpage | 111 | - |
dc.citation.volume | 342 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Jae-Young | - |
dc.contributor.affiliatedAuthor | Kim, Dae-Duk | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | BOUND PACLITAXEL | - |
dc.subject.keywordPlus | CREMOPHOR-FREE | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | PHASE | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | ABI-007 | - |
dc.subject.keywordAuthor | Bone tumors | - |
dc.subject.keywordAuthor | Alendronate | - |
dc.subject.keywordAuthor | Human serum albumin | - |
dc.subject.keywordAuthor | Nanoclusters | - |
dc.subject.keywordAuthor | Hydroxyapatite | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.